CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer

Oncology Reports

Volumn 22, Issue 4, 2009, Pages 745-755

  Okayama, Hirokazu ^a   Kumamoto, Kensuke ^a   Saitou, Katsuharu ^a   Hayase, Suguru ^a   Kofunato, Yasuhide ^a   Sato, Yu ^a   Miyamoto, Kotaro ^a   Nakamura, Izumi ^a   Ohki, Shinji ^a   Sekikawa, Kouji ^b   Takenoshita, Seiichi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b Kawasaki Saiwai Hospital   (Japan)

Author keywords

CD44v6; Cdx2; Gastric cancer; Lymph node metastasis; MMP 7

Indexed keywords

CD44V6 ANTIGEN; CYCLIN B1; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERCELLULAR ADHESION MOLECULE 1; MATRILYSIN; NUCLEOSIDE DIPHOSPHATE KINASE NM23; ONCOPROTEIN; PROTEIN RCAS1; RECEPTOR BINDING CANCER ANTIGEN EXPRESSED ON SISO CELL; SURVIVIN; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; CDX2 PROTEIN, HUMAN; CXCL5 PROTEIN, HUMAN; CYCLIN B; EBAG9 PROTEIN, HUMAN; HERMES ANTIGEN; HOMEODOMAIN PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NME1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DISEASE MARKER; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; STOMACH CANCER; TISSUE DIFFERENTIATION; ADENOCARCINOMA; AGED; BIOSYNTHESIS; CELL NUCLEUS; LYMPH NODE; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CELL NUCLEUS; CHEMOKINE CXCL5; CYCLIN B; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 7; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70350746167     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000496     Document Type: Article

References (75)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002 CA Cancer J Clin 55: 74-108, 2005.
2. Yokota T, Ishiyama S, Saito T, Teshima S, Narushima Y, Murata K, Iwamoto K, Yashima R, Yamauchi H and Kikuchi S: Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol 39: 380-384, 2004.
3. Kim JP, Hur YS and Yang HK: Lymph node metastasis as a significant prognostic factor in early gastric cancer: analysis of 1,136 early gastric cancers. Ann Surg Oncol 2: 308-313, 1995.
4. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA and Hamilton SM: Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 241: 27-39, 2005.
5. Jansen EP, Boot H, Verheij M and van de Velde CJ: Optimal locoregional treatment in gastric cancer. J Clin Oncol 23: 4509-4517, 2005.
6. McCulloch P, Niita ME, Kazi H and Gama-Rodrigues JJ: Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg 92: 5-13, 2005.
7. Soetikno R, Kaltenbach T, Yeh R and Gotoda T: Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol 23: 4490-4498, 2005.
8. Kim MC, Kim KH, Kim HH and Jung GJ: Comparison of laparoscopy-assisted by conventional open distal gastrectomy and extraperigastric lymph node dissection in early gastric cancer. J Surg Oncol 91: 90-94, 2005.
9. Aruffo A, Stamenkovic I, Melnick M, Underhill CB and Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313, 1990.
10. Hofmann M, Rudy W, Zoller M, Tolg C, Ponta H, Herrlich P and Gunthert U: CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 51: 5292-5297, 1991.
11. Muller W, Schneiders A, Heider KH, Meier S, Hommel G and Gabbert HE: Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J Pathol 183: 222-227, 1997.
12. Hong RL, Lee WJ, Shun CT, Chu JS and Chen YC: Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas. Oncology 52: 334-339, 1995.
13. Kurozumi K, Nishida T, Nakao K, Nakahara M and Tsujimoto M: Expression of CD44 variant 6 and lymphatic invasion: importance to lymph node metastasis in gastric cancer. World J Surg 22: 853-857, 1998.
14. Castella EM, Ariza A, Pellicer I, Fernandez-Vasalo A and Ojanguren I: Differential expression of CD44v6 in metastases of intestinal and diffuse types of gastric carcinoma. J Clin Pathol 51: 134-137, 1998.
15. Joo M, Lee HK and Kang YK: Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis. Anticancer Res 23: 1581-1588, 2003.
16. Staunton DE, Marlin SD, Stratowa C, Dustin ML and Springer TA: Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 52: 925-933, 1988.
17. Staunton DE, Dustin ML, Erickson HP and Springer TA: The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell 61: 243-254, 1990.
18. Vanky F, Wang P, Patarroyo M and Klein E: Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother 31: 19-27, 1990.
19. Jackson AM, Alexandrov AB, Gribben SC, Esuvarnathan K and James K: Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy. Int J Cancer 55: 921-925, 1993.
20. Maruo Y, Gochi A, Kaihara A, Shimamura H, Yamada T, Tanaka N and Orita K: ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer. Int J Cancer 100: 486-490, 2002.
21. Yashiro M, Sunami T and Hirakawa K: CD54 expression is predictive for lymphatic spread in human gastric carcinoma. Dig Dis Sci 50: 2224-2230, 2005.
22. Suh E and Traber PG: An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol 16: 619-625, 1996.
23. Eda A, Osawa H, Yanaka I, Satoh K, Mutoh H, Kihira K and Sugano K: Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J Gastroenterol 37: 94-100, 2002.
24. Mutoh H, Sakurai S, Satoh K, Tamada K, Kita H, Osawa H, Tomiyama T, Sato Y, Yamamoto H, Isoda N, Yoshida T, Ido K and Sugano K: Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice. Cancer Res 64: 7740-7747, 2004.
25. Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, Sackett SD and Kaestner KH: Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 122: 689-696, 2002.
26. Mizoshita T, Tsukamoto T, Nakanishi H, Inada K, Ogasawara N, Joh T, Itoh M, Yamamura Y and Tatematsu M: Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis. J Cancer Res Clin Oncol 129: 727-734, 2003.
27. Seno H, Oshima M, Taniguchi MA, Usami K, Ishikawa TO, Chiba T and Taketo MM: CDX2 expression in the stomach with intestinal metaplasia and intestinal-type cancer: prognostic implications. Int J Oncol 21: 769-774, 2002.
28. Fan Z, Li J, Dong B and Huang X: Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin Cancer Res 11: 6162-6170, 2005.
29. Kakinuma T and Hwang ST: Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 79: 639-651, 2006.
30. Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS and Yeudall WA: Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res 66: 4279-4284, 2006.
31. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM and Macoska JA: CXCL5 promotes prostate cancer progression. Neoplasia 10: 244-254, 2008.
32. Speetjens FM, Kuppen PJ, Sandel MH, Menon AG, Burg D, van de Velde CJ, Tollenaar RA, de Bont HJ and Nagelkerke JF: Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin Cancer Res 14: 2276-2284, 2008.
33. Park JY, Park KH, Bang S, Kim MH, Lee JE, Gang J, Koh SS and Song SY: CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol 133: 835-840, 2007.
34. Patel V, Jakus J, Harris CM, Ensley JF, Robbins KC and Yeudall WA: Altered expression and activity of G1/S cyclins and cyclin-dependent kinases characterize squamous cell carcinomas of the head and neck. Int J Cancer 73: 551-555, 1997.
35. Nielsen NH, Arnerlov C, Emdin SO and Landberg G: Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 74: 874-880, 1996.
36. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK and Mao L: Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 60: 4000-4004, 2000.
37. Wang A, Yoshimi N, Ino N, Tanaka T and Mori H: Over-expression of cyclin B1 in human colorectal cancers. J Cancer Res Clin Oncol 123: 124-127, 1997.
38. Korenaga D, Takesue F, Yasuda M, Honda M, Nozoe T and Inutsuka S: The relationship between cyclin B1 over-expression and lymph node metastasis in human colorectal cancer. Surgery 131: S114-S120, 2002.
39. Yasuda M, Takesue F, Inutsuka S, Honda M, Nozoe T and Korenaga D: Overexpression of cyclin B1 in gastric cancer and its clinicopathological significance: an immunohistological study. J Cancer Res Clin Oncol 128: 412-416, 2002.
40. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
41. Shiomi T and Okada Y: MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Met Rev 22: 145-152, 2003.
42. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y and Imai K: Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 45: 252-258, 1999.
43. Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, Arimura Y, Endo T, Hinoda Y, Hosokawa M and Imai K: Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 59: 3313-3316, 1999.
44. Ajisaka H, Yonemura Y and Miwa K: Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer. Hepatogastroenterology 51: 900-905, 2004.
45. Aihara R, Mochiki E, Kamiyama Y, Ohno T, Asao T and Kuwano H: Matrilsin expression is a useful marker of submucosal invasion and lymph node metastasis in early stage signet ring cell carcinoma of the stomach. J Surg Oncol 93: 491-497, 2006.
46. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA and Sobel ME: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80: 200-204, 1988.
47. Hirayama R, Sawai S, Takagi Y, Mishima Y, Kimura N, Shimada N, Esaki Y, Kurashima C, Utsuyama M and Hirokawa K: Positive relationship between expression of anti-metastatic factor (nm23 gene product or nucleoside diphosphate kinase) and good prognosis in human breast cancer. J Natl Cancer Inst 83: 1249-1250, 1991.
48. Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A, Vives J, Cardesa A and Yague J: Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas. Cancer 73: 2913-2921, 1994.
49. Nakayama T, Ohtsuru A, Nakao K, Shima M, Nakata K, Watanabe K, Ishii N, Kimura N and Nagataki S: Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product. J Natl Cancer Inst 84: 1349-1354, 1992.
50. Bosnar MH, Pavelic K, Krizanac S, Slobodnjak Z and Pavelic J: Squamous cell lung carcinomas: the role of nm23-H1 gene. J Mol Med 75: 609-613, 1997.
51. Engel M, Theisinger B, Seib T, Seitz G, Huwer H, Zang KD, Welter C and Dooley S: High levels of nm23-H1 and nm23-H2 messenger RNA in human squamous-cell lung carcinoma are associated with poor differentiation and advanced tumor stages. Int J Cancer 55: 375-379, 1993.
52. Kodera Y, Isobe K, Yamauchi M, Kondoh K, Kimura N, Akiyama S, Itoh K, Nakashima I and Takagi H: Expression of nm23 H-1 RNA levels in human gastric cancer tissues. A negative correlation with nodal metastasis. Cancer 73: 259-265, 1994.
53. Hsu NY, Chow KC, Chen WJ, Lin CC, Chou FF and Chen CL: Expression of nm23 in the primary tumor and the metastatic regional lymph nodes of patients with gastric cardiac cancer. Clin Cancer Res 5: 1752-1757, 1999.
54. Muller W, Schneiders A, Hommel G and Gabbert HE: Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis. Cancer 83: 2481-2487, 1998.
55. Monig SP, Nolden B, Lubke T, Pohl A, Grass G, Schneider PM, Dienes HP, Holscher AH and Baldus SE: Clinical significance of nm23 gene expression in gastric cancer. Anticancer Res 27: 3029-3033, 2007.
56. Nakashima M, Sonoda K and Watanabe T: Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 5: 938-942, 1999.
57. Okada K, Nakashima M, Komuta K, Hashimoto S, Okudaira S, Baba N, Hishikawa Y, Koji T, Kanematsu T and Watanabe T: Expression of tumor-associated membrane antigen, RCAS1, in human colorectal carcinomas and possible role in apoptosis of tumor-infiltrating lymphocytes. Mod Pathol 16: 679-685, 2003.
58. Iwasaki T, Nakashima M, Watanabe T, Yamamoto S, Inoue Y, Yamanaka H, Matsumura A, Iuchi K, Mori T and Okada M: Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int J Cancer 89: 488-493, 2000.
59. Nakamura Y, Yamazaki K, Oizumi S, Nakashima M, Watanabe T, Dosaka-Akita H and Nishimura M: Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape. Cancer Sci 95: 260-265, 2004.
60. Fukuda K, Tsujitani S, Maeta Y, Yamaguchi K, Ikeguchi M and Kaibara N: The expression of RCAS1 and tumor infiltrating lymphocytes in patients with T3 gastric carcinoma. Gastric Cancer 5: 220-227, 2002.
61. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM and Ryan BM: Survivin: a promising tumor biomarker. Cancer Lett 249: 49-60, 2007.
62. Altieri DC: New wirings in the survivin networks. Oncogene 27: 6276-6284, 2008.
63. Miyachi K, Sasaki K, Onodera S, Taguchi T, Nagamachi M, Kaneko H and Sunagawa M: Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastric Cancer 6: 217-224, 2003.
64. Lee GH, Joo YE, Koh YS, Chung IJ, Park YK, Lee JH, Kim HS, Choi SK, Rew JS, Park CS and Kim SJ: Expression of survivin in gastric cancer and its relationship with tumor angiogenesis. Eur J Gastroenterol Hepatol 18: 957-963, 2006.
65. Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE and Gerharz CD: Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 86: 737-743, 2002.
66. Lu CD, Altieri DC and Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58: 1808-1812, 1998.
67. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M and Takano Y: Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 163: 109-116, 2001.
68. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma, 2nd English edition. Gastric Cancer 1: 10-24, 1998.
69. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991.
70. Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K, Sasaki I and Matsuno S: Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 91: 67-75, 2001.
71. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P and Pals ST: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53: 4754-4756, 1993.
72. Wilson CL and Matrisian LM: Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 28: 123-136, 1996.
73. Ii M, Yamamoto H, Adachi Y, Maruyama Y and Shinomura Y: Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 231: 20-27, 2006.
74. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52: 6735-6740, 1992.
75. Liu Q, Teh M, Ito K, Shah N, Ito Y and Yeoh KG: CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cancer. Mod Pathol 20: 1286-1297, 2007.